GENE ONLINE|News &
Opinion
Blog

Spotlight: Roche’s SMA Drug, Risdiplam Makes Strong Case for Regulatory Approval

by GeneOnline
Share To
Spinal muscular atrophy (SMA), a motor neuron disease, is the leading inherited cause of death in newborns, affecting approximately one in 10,000 individuals. In SMA patients, recessive loss-of-function mutations in the survival motor neuron 1 gene (SMN1) results in a reduced amount of functional SMN protein, which then leads to loss of α motor neurons and severe muscle weakness, particularly in proximal, truncal, and bulbar muscle groups. In patients with the most severe infantile-onset form (type I), infants do not survive beyond the first two years of life due to progressive hypotonia,

GO Prime with only $1.49 now

LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
EVENT
Scroll to Top